Yarrow Bioscience (YARW) Stock Price, News & Analysis

Company Overview

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Key Stats

• Today's Range: $15.65 to $19.00
• 50-Day Range: $13.60 to $30.58
• 52-Week Range: $12.39 to $46.95
• Volume: 187,307 shs
• Average Volume: 186,875 shs
• Market Capitalization: $48.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $59.00
• Consensus Rating: Moderate Buy

Yarrow Bioscience Stock Analysis - MarketRank™

Yarrow Bioscience scored higher than 43% of companies evaluated by MarketBeat, and ranked 606th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Yarrow Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Yarrow Bioscience has a consensus price target of $59.00, representing about 226.9% upside from its current price of $18.05.

Amount of Analyst Coverage

Yarrow Bioscience has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Yarrow Bioscience has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.48% of the float of Yarrow Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Yarrow Bioscience has a short interest ratio ("days to cover") of 0.83, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Yarrow Bioscience has recently increased by 7.52%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Yarrow Bioscience does not currently pay a dividend.

Dividend Growth

Yarrow Bioscience does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.47

News Sentiment

Yarrow Bioscience has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Yarrow Bioscience this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Yarrow Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.03% of the stock of Yarrow Bioscience is held by insiders.

Percentage Held by Institutions

83.78% of the stock of Yarrow Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:YARW
• Previous Symbol: NASDAQ:VYNE
• CIK: 1566044
• Web: www.yarrowbioscience.com
• Phone: (203) 433-7577
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Yarrow Bioscience: $59.00
• High Price Target: $60.00
• Low Price Target: $58.00
• Potential Upside/Downside: +226.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($14.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.48 million
• Net Margins: -4,726.21%
• Pretax Margin: -4,900.26%
• Return on Equity: -84.40%
• Return on Assets: -77.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.26
• Quick Ratio: 15.26

Sales & Book Value

• Annual Sales: $570 thousand
• Price / Sales: 84.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $41.71 per share
• Price / Book: 0.43

Miscellaneous

• Outstanding Shares: 2,670,000
• Free Float: 2,589,000
• Market Cap: $48.19 million
• Optionable: N/A
• Beta: 2.10